Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2NET 2Gynecologic 2Endocrine 2Sarcoma 1Other solid neoplasm 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 206Colonic Neoplasms 89Rectal Neoplasms 88Stomach Neoplasms 57Pancreatic Neoplasms 49Neoplasms 42Esophageal Neoplasms 42Neoplasm Metastasis 39Unspecified Adult Solid Tumor, Protocol Specific 30Lung Neoplasms 28Glioblastoma 27Brain Neoplasms 26Carcinoma, Non-Small-Cell Lung 24Central Nervous System Neoplasms 23Glioma 22Small Cell Lung Carcinoma 21Neuroblastoma 20Astrocytoma 18Adenocarcinoma Of Esophagus 18Esophageal Squamous Cell Carcinoma 17Gliosarcoma 16Breast Neoplasms 15Rhabdomyosarcoma 13Oligodendroglioma 12Sarcoma 11Adenocarcinoma 10Medulloblastoma 9Carcinoma, Hepatocellular 9Sarcoma, Ewing 8Gastrointestinal Neoplasms 8

Interventions

Everolimus 17lutetium Lu 177 dotatate 7Octreotide 7pasireotide 6lanreotide 6gallium Ga 68 dotatate 5Temozolomide 5Sunitinib 5Positron Emission Tomography Computed Tomography 5surufatinib 4pembrolizumab 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neuroendocrine Tumors × Irinotecan × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡